No Data
Recent market hotspots continue to rotate between high and low, focusing on varieties with certainty in mid-term report performance.
Track the entire lifecycle of the main Sector.
[Special Contributor] Deng Shengxing: There is no sign of a ceasefire in the Iraq War, and Hong Kong stocks are unable to rise.
Jin Wu Financial News | The Hang Seng Index closed at 23,237 on Thursday (19th), down 472 points or 2%. The total market turnover for the day was 220 billion yuan. The National Index fell by 2.1% to 8,410; the Tech Index dropped by 2.4% to 5,088. The biotechnology stock index declined for the fifth consecutive day, falling another 3.1% today, with CSPC Pharmaceutical (01093) dropping 6.4% to close at 7.61 yuan, making it the worst-performing blue chip; only Hang Lung Properties (00012) and K. Wah International (01997) recorded gains, with Hang Lung closing at 26.7 yuan, up 0.4%; K. Wah rose 1.2% to close at 21.3 yuan, being the best-performing blue chip.
ASCENTAGE-B (6855.HK): Innovative products showcased at the ASCO conference, with core pipeline driving company growth.
At the 2025 ASCO Annual Meeting, the company's core product Lisaftoclax showcased research results in patients who were resistant to venetoclax. Among 28 patients previously treated with venetoclax, 22.
Quick View of the Hong Kong Market | All three major indices fell, the Tech Index dropped by 2.42%; Network Technology stocks weakened, Meituan fell nearly 4%; New consumption Concept stocks corrected, MAO GEPING and Lao Pu Gold both fell over 6%.
Network Technology stocks fell broadly, with MEITUAN-W down 3.75% and JD-SW down 3.63%; Securities and Brokerage stocks declined, with HOLLY FUTURES dropping 6.58% and BRIGHT SMART down 5.68%; biotechnology stocks also saw declines, with ZAI LAB down 6.96% and BEIGENE down 4.46%.
Hong Kong stock midday review | All three major indices fell, the Index dropped by 2.38%; Network Technology stocks weakened, JD.com declined nearly 4%; New consumption Concept stocks corrected, POP MART fell more than 5%.
Network Technology stocks generally fell, with JD-SW down 3.79% and Bilibili-W down 3.43%; biotechnology stocks weakened, with ZAI LAB down 6.96% and REMEGEN down 4.84%; most Digital Health stocks declined, with Dingdang Health down 10.34% and ALI HEALTH down 4.82%.
Value "reassessment" is in progress! A surge of double stocks in the Hong Kong stock market's innovative drug Concept is emerging. Where are the opportunities for the Sector in the future?
After more than three years of downturn, innovative drugs in the Hong Kong stock market have welcomed an opportunity for value reassessment.
